Pyridoxine Improves Drug-Induced Parkinsonism and Psychosis in a Schizophrenic Patient

References

• Adams P. W., Rose D. P., Folkard J., Wynn V., Seed M., Strong R. Effect of pyridoxinc hydrochloride (vitamin B6) upon depression associated with oral contraception. Lancet 1973; 1: 897–904
   Web of Science ®Google Scholar
• Anton-Tay F. Pineal-brain relationship. The pineal gland, G. E.W. Wolstenholme, J. Knight. Churchill Livingstone, Edinburgh and London 1971; 213–220
   Google Scholar
• Anton-Tay F., Chou C., Anton S., Wurtman R. J. Brain serotonin concentrations: elevation following intraperitoneal administration of melatonin. Science 1968; 162: 277–278
   PubMed Web of Science ®Google Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Axelrod J. Introductory remarks on regulation of pineal indoleamine synthesis. Journal of Neural Transmission 1978; 13: 73–79, (suppl)
   Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Bacopoulos N. G. Antipsychotic drug effects on dopamine and serotonin rccepotors: in vitro binding and in vivo turnover studies. Journal of Pharmacology and Experimental Therapeutics 1981; 219: 708–714
   PubMed Web of Science ®Google Scholar
• Bauernfeid J. C., Miller O. N. Vitamin B6: Nutritional and pharmaceutical usage, stability. bioavailability, antagonists, and safety. Human vitamin B6 Requirements. National Academy of Sciences, Washington, DC 1978; 78–110
   Google Scholar
• Bennett J. P., Enna S. J., Bylunnd D., Gillin J. C., Wyatt R. J., Snyder S. H. Neurotransmitter receptors in frontal cortex of schizophrenia. Archives of General Psychiatry 1979; 36: 927–934
   PubMed Web of Science ®Google Scholar
• Bianchine J. R. Drugs for Parkinson's disease, spasticity, and acute muscle spasms. The Pharmacological Basis of Therapeutics7th Edition, A. G. Gilman, L. S. Goodman, T. W. Rail, F. Murad. Macmillan Publ, New York 1985; 473–490
   Google Scholar
• Bruno A., Bruno S. C. Effects of L-dopa on pharmacological Parkinsonism. Acta Psychiatrica Scandinavica 1966; 42: 264–271
   PubMedGoogle Scholar
• Carlsson A., Lundqvist M. Effect of chlopromazine or haloperidol on formation of 3-methoxytryptamine and normetanephrinc in mouse brain. Acta Pharmacolgica and Toxicologica 1963; 20: 140–144
   PubMedGoogle Scholar
• Catterall W. F. Tryptophan and bladder cancer. Biological Psychiatry 1988; 24: 721–734
   PubMedGoogle Scholar
• Chase T. N., Schnur J. A., Gordon E. K. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology 1970; 9: 265–268
   PubMed Web of Science ®Google Scholar
• Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of Parkinsonism. New England Journal of Medicine 1967; 276: 374–379
   PubMed Web of Science ®Google Scholar
• Cremer-Bartels G., Ebels I., Sykes J. E. C., de Moree A. Effects of retinal and pineal low molecular weight fractions and antipsychotic drugs on hydrozyindole-O-methyltransferase. Journal of Neural Transmission 1983; 58: 107–119
   PubMed Web of Science ®Google Scholar
• Crow T. J., Johnstone E. C., McClelland H. A. The coincidence of schizophrenia and Parkinsonism: Some neurochemical implications. Psychological Medicine 1976; 6: 227–233
   PubMed Web of Science ®Google Scholar
• Dakshinamuri K., LeBlancq W. D., Herchl R., Havlicek V. Nonparallel changes in brain monoamines of pyridoxine-deficicnt growing rats. Eexperimental Brain Research 1976; 26: 355–366
   PubMedGoogle Scholar
• Dakshinamurti K., Stephens M. C. Pyridoxine deficiency in the neonatal rat. Journal of Neurochemistry 1969; 16: 1515–1522
   PubMed Web of Science ®Google Scholar
• Datta P. C., King M. G. Melatonin: Effects on brain and behavior. Neuroscience & Biohehavioural Review 1980; 4: 451–458
   PubMed Web of Science ®Google Scholar
• Dray A. Serotonin in the basal ganglia. Journal of PhysioIogy(Paris) 1981; 77: 393–403
   Google Scholar
• Dreyfus P. M., Geel S. E. Vitamins and nutritional deficiencies. Basic neurochemistrv, G. J. Siegel, R. W. Alberts, B. W. Agranoff, R. Katzman. Little Brown, Boston 1981; 661–679
   Google Scholar
• Ellis J., Folkers K., Watanabe T., Kaji M., Saji S., Caldwell J. W., Temple C. A., Wood F. S. Clinical results of a cross-over treatment with pyridoxine and placebo in the carpal tunnel syndrome. American Journal of Clinical Nutrition 1979; 32: 2040–2046
   PubMed Web of Science ®Google Scholar
• Ferrier I. N., Arendt J., Johnstone E. C., Crow T. J. Reduced nocturnal melatonin secretion in chronic schizophrenia: Relationship to body weight. Clinical Endocrinology 1982; 17: 181–187
   PubMed Web of Science ®Google Scholar
• Fibiger H. C., Lloyd K. G. Neurobiological substrates of tardive dyskinesia: theGABA hypothesis. Trends in Neurosciences 1984; 7: 462–464
   Web of Science ®Google Scholar
• Fischer P. A., Schneider E., Jacobi P., Maxion H. Effect of melanocyte-stimulating hormone-relase inhibiting factor (MIF) in Parkinson's syndrom. European Neurology 1974; 12: 360–368
   PubMed Web of Science ®Google Scholar
• Flemming P., Makar H., Hunter K. R. Levodopa in drug induced extrapyramidal disorders. Lancet 1970; 2: 1186
   Google Scholar
• Hardie R. J., Lees A. J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology Neurosurgery & Psychiatry 1988; 51: 850–854
   PubMed Web of Science ®Google Scholar
• Hartley R., Padwick D., Smith J. A. The inhibition of pineal hydroxindole-O-methyltransferase by haloperidol and fluphenazine. Journal of Pharmacology and Pharmacy 1972; 24: 100P–103P, (suppl)
   Web of Science ®Google Scholar
• Hausner R. S. Neuroleptic-induced Parkinsonism and Parkinson's disease: differential diagnosis and treatment. Journal of Clincial Psychiatry 1983; 44: 13–16
   PubMed Web of Science ®Google Scholar
• Henderson L. M., Hulse J. D. Vitamin B6: Relationship to tryptophan metabolism. Human vitamin B6 Requirements. National Academcy of Science, Washington, DC 1978; 21–36
   Google Scholar
• Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic-induced Parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
   PubMed Web of Science ®Google Scholar
• Johnson D. A.W. Prevalence and treatment of drug-induced extrapyramidal symptoms. British Journal of Psychiatry 1978; 132: 27–30
   Web of Science ®Google Scholar
• Kane J. M., Woerner M., Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988; 8: 52S–56S, (suppl)
   PubMed Web of Science ®Google Scholar
• King R., Faull K. F., Stahl S. M., Mefford I. N., Thiemann S., Barchas J., Berger P. A. Serotonin and schizophrenia: correlations between serotonergic activity and schizophrenic motor behavior. Psychiatry Research 1985; 14: 235–240
   PubMed Web of Science ®Google Scholar
• Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
   PubMed Web of Science ®Google Scholar
• Kozell L., Sandyk R., Wagner G. C., Fisher H. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat. Life Sciences 1987; 41: 1739–1744
   PubMed Web of Science ®Google Scholar
• Leysen J. E., Niemegeers C. J., Tollenaerc J. P., Laduron P. M. Serotonergic component of neuroleptic receptors. Nature 1978; 272: 168–171
   PubMed Web of Science ®Google Scholar
• Li T. Factors influencing vitamin B6 requirements in alcoholism. Human B6 requirements. National Academy of Science, Washington, DC 1978; 210–225
   Google Scholar
• Marcus R., Coulson A. M. Water-solube vitamins. The vitamin B complex and ascorbic acid. The pharmacological basis of therapeutics7th Edition, A. G. Gilman, L. S. Goodman, T. W. Rail, F. Murad. Macmillan Publishing Company, New York 1985; 1551–1572
   Google Scholar
• McLelland H. A. Discussion on assessment of drug-induced extrapyramidal reactions. British Journal of Clinical Pharmacology 1976; 401–403, suppl
   PubMed Web of Science ®Google Scholar
• Meerwaldt J. D. Treatment of hypokinetic rigid syndrome with fluvoxamine maleate. Lancet 1986; 2: 977–978
   Google Scholar
• Mena I., Court J., Fuenzalida S., Papavasilou P. S., Cotzias G. C. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophan. New England Journal of Medicine 1970; 282: 5–10
   PubMed Web of Science ®Google Scholar
• Miles A., Philbrick D. R.S. Melatonin in psychiatry. Biological Psychiatry 1988; 23: 405–425
   PubMed Web of Science ®Google Scholar
• Mita T., Hanada S., Nishino N., Kuno T., Nakai H., Yamadori T., Mizoi Y., Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenia. Biological Psychiatry 1986; 21: 1407–1414
   PubMed Web of Science ®Google Scholar
• Nelson D. L., Pedigo N. W., Yamamura H. I. Multiple 3H-5-hydroxytryptamine binding sites in the rat brain. Journal of Physiology, (Paris) 1981; 77: 369–372
   PubMedGoogle Scholar
• Owens D. G. C., Johnstone E. C., Crow T. J., Frith C. D., Jagoe J. R., Kreel L. Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychological Medicine 1985; 15: 27–41
   PubMed Web of Science ®Google Scholar
• Peroutka S. J., Snyder S. H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, aplhaadrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry 1980; 137: 1518–1522
   PubMed Web of Science ®Google Scholar
• Potkin S. G., Weinberger D. R., Linnoila M., Wyatt R. J. Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry 1983; 140: 21–25
   PubMed Web of Science ®Google Scholar
• Rajput A. H., Rozdilsky B., Jornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced Parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
   PubMedGoogle Scholar
• Richardson M. A., Craig T. J. The coexistence of Parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
   PubMed Web of Science ®Google Scholar
• Roberts E. Some thoughts about the gamma-aminobutyric acid system in nervous tissue. Nutrition Review 1963; 21: 161–165
   PubMedGoogle Scholar
• Rose D. P. Oral contraceptives and vitamin B6. In Human B6 Requirements. National Academy of Science, Washington, DC 1978; 193–201
   Google Scholar
• Sack R. L., Lewy A. J., Erb D. L., Vollmer W. M., Singer C. M. Human melatonin production decreases with age. Journal of Pineal Research 1986; 3: 379–388
   PubMed Web of Science ®Google Scholar
• Samanin R., Quaattrone A., Peri G., Ladinsky H., Consolo S. Evidence of an interaction between serotonergic and cholinergic neurons in the corpus striatum and hippocampus of the rat brain. Brain Research 1978; 151: 73–82
   PubMed Web of Science ®Google Scholar
• Sandyk R., Consroe P., Iacono R. P. L-tryptophan in drug-induced movement disorders with insomnia. New England Journal of Medicine 1986; 314: 1257
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Serotonin in involuntary movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R. Attenuation of reserpine-induced catalepsy by melatonin and the role of the opioid system. International Journal of Neuroscience 1989; 48: 297–301
   PubMed Web of Science ®Google Scholar
• Sano V. I., Tanguchi K. L-5-hydroxytryptophan (5-HTP) Therapie des Morbus Parkinson. Munschner Wochenschrift 1972; 114: 1717–1719
   PubMedGoogle Scholar
• Schaumberg J., Kaplan J., Windebank A., Vick N., Rasmus S., Pleasure D., Brown M. J. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. New England Journal of Medicine 1983; 309: 445–448
   PubMed Web of Science ®Google Scholar
• Shuster S., Thody A. J., Goolamali S. K., Burton J. L., Plummer N., Bates D. Melanocytestimulating hormone and parkinsonism. Lancet 1973; 1: 463–465
   PubMed Web of Science ®Google Scholar
• Siow Y. L., Dakshinamurti K. Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in adult rat brain. Experimental Brain Research 1985; 59: 575–581
   PubMedGoogle Scholar
• Stephen P. J., Williamson J. Drug-induced Parkinsonism in the elderly. Lancet 1984; 1: 1082–1083
   Google Scholar
• Stewart J. W., Harrison W., Quitkin F., Baker H. Low B6 levels in depressed outpatients. Biological Psychiatry 1984; 19: 613–616
   PubMed Web of Science ®Google Scholar
• Viswanathan M., Siow Y. L., Paulose C. S., Dakshinamurti K. Pineal indoleamine metabolism in pyridoxine-deficient rats. Brain Research 1988; 473: 37–42
   PubMed Web of Science ®Google Scholar
• Yahr M. D. Levodopa. Annals of Internal Medicine 1975; 83: 677–682
   PubMedGoogle Scholar